PatrĂ­cia Silva, PhD,  director of science content—

PatrĂ­cia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĂ­cia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by PatrĂ­cia Silva

Walgreens Offers ‘CF Champions’ to Help Cystic Fibrosis Patients Better Meet Everyday Challenges

Walgreens is launching CF Champions: Navigating the Journey, Together, a program to support patients, caregivers and all who have been touched by cystic fibrosis (CF). The initiative runs throughout May, the Cystic Fibrosis Foundation’s National CF Awareness Month, and possibly through the end of this year. Walgreens partnered with four CF…

CF Foundation Leaders and Advocates Hear Latest on Precision Medicine at White House Summit

Cystic Fibrosis Foundation leaders and cystic fibrosis (CF) community advocates met at the White House with President Barack Obama, officials from the National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA), and other CF stakeholders last month for the Precision Medicine Initiative (PMI) Summit. The summit was an opportunity…

CF Foundation Honors Community Leaders in North Carolina at 6th Annual Standout Awards Banquet

The Cystic Fibrosis Foundation (CF Foundation) honored professionals in the Charlotte, North Carolina, area for their business, community leadership, and philanthropy work at its Sixth Annual STANDOUT Awards banquet, with proceeds from the 2015 event going to further the Foundation’s research, care, and educational programs for cystic fibrosis (CF). A banquet highlight was the…

New Insights into Cystic Fibrosis-related Chronic Lung Infections Likely to Lead to Better Therapies

Better ways of treating chronic lung infections in patients with cystic fibrosis (CF) are likely to result from scientific advances in the understanding of how Pseudomonas aeruginosa bacteria evolve and adapt during infections, according to a recently published review from the University of Liverpool, working in collaboration with the University of York. The review appeared in…

18 CF Groups Chosen by Vertex to Receive ‘Cystic Fibrosis Circle of Care’ Grants Totaling Almost $1M

Vertex Pharmaceuticals, Inc.  recently announced that 18 nonprofit groups were chosen to receive Cystic Fibrosis (CF) Circle of Care grants for 2016, totaling nearly $1 million. The award, now in its second year, is given to medical, academic, patient, and community organizations aiding the cystic fibrosis (CF) community. Despite recent…

Potential Cystic Fibrosis Treatment, Now in Phase 2 Study, Granted ‘Fast Track’ Designation by FDA

Nivalis Therapeutics, Inc., recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational drug, N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, as a potential treatment for patients with cystic fibrosis (CF). The drug is now being evaluated in…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.